AL-2846 is under clinical development by Advenchen Laboratories and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AL-2846’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-2846 overview
AL-2846 is under development for the treatment of solid tumor, gastric cancer, breast cancer, renal cell carcinoma, advanced pancreatic cancer, colon cancer, advanced non-small cell lung cancer, ovarian cancer, breast cancer, prostate cancer, bladder cancer, differentiated thyroid cancer, medullary thyroid cancer, type I neurofibromatosis related neurofibromatosis and peripheral malignant nervous sheath tumor. It is formulated as a capsule and is administered through oral route. It acts by targeting c-Met receptor tyrosine kinase (RTK), Flt4 (VEGFR-3), KDR (VEGFR-2) and Ron.
See Also:
It was also under development for gastric cancer, renal cell carcinoma and breast cancer.
Advenchen Laboratories overview
Advenchen Laboratories is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.
For a complete picture of AL-2846’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
